Nanotechnology-enabled gene delivery for cancer and other genetic diseases

References

• NALDINI L. Gene therapy returns to centre stage. Nature. 2015;526(7573):351–360.
   PubMed Web of Science ®Google Scholar
• BURNETT JC, ROSSI JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60–71.
   PubMed Web of Science ®Google Scholar
• MUHONEN P, HOLTHOFER H. Bioinformatic approaches to siRNA selection and optimization. Methods Mol Biol. 2010;623:93–107.
   PubMedGoogle Scholar
• BESSIS N, GARCIACOZAR FJ, BOISSIER MC. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Genet Ther. 2004;11 Suppl 1:S10–7.
   PubMed Web of Science ®Google Scholar
• BAUM C, KUSTIKOVA O, MODLICH U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17(3):253–263. DOI:10.1089/hum.2006.17.253
   PubMed Web of Science ®Google Scholar
• YIN H, KANASTY RL, ELTOUKHY AA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541–555. DOI:10.1038/nrg3763
   PubMed Web of Science ®Google Scholar
• DAKA A, PEER D. Rnai-based nanomedicines for targeted personalized therapy. Adv Drug Delivery Rev. 2012;64(13):1508–1521.
   PubMed Web of Science ®Google Scholar
• KANASTY R, DORKIN JR, VEGAS A, et al. Delivery materials for siRNA therapeutics. Nat Mater. 2013;12(11):967–977. DOI:10.1038/nmat3765
   PubMed Web of Science ®Google Scholar
• KIM HJ, KIM A, MIYATA K, et al. Recent progress in development of siRNA delivery vehicles for cancer therapy. Adv Drug Delivery Rev. 2016;104:61–77.
   PubMed Web of Science ®Google Scholar
• MORITA K, HASEGAWA C, KANEKO M, et al. 2’-O,4’-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett. 2002;12(1):73–76. DOI:10.1016/S0960-894X(01)00683-7
   PubMed Web of Science ®Google Scholar
• SETH PP, VASQUEZ G, ALLERSON CA, et al. Synthesis and biophysical evaluation of 2‘,4’-constrained 2‘O-methoxyethyl and 2‘,4’-constrained 2‘O-ethyl nucleic acid analogues. J Org Chem. 2010;75(5):1569–1581. DOI:10.1021/jo902560f
   PubMed Web of Science ®Google Scholar
• PRAKASH TP. An overview of sugar-modified oligonucleotides for antisense therapeutics. Chem Biodivers. 2011;8(9):1616–1641.
   PubMed Web of Science ®Google Scholar
• Ku SH, Jo SD, Lee YK, et al. Chemical and structural modifications of RNAi therapeutics. Adv Drug Delivery Rev. 2016;104:16–28.
   PubMed Web of Science ®Google Scholar
• WHITEHEAD KA, DAHLMAN JE, LANGER RS, et al. Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng. 2011;2:77–96.
   PubMed Web of Science ®Google Scholar
• GARBER K. Worth the RISC? Nature Biotechnol. 2017;35(3):198–202.
   PubMed Web of Science ®Google Scholar
• LI SD, HUANG L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008;5(4):496–504.
   PubMed Web of Science ®Google Scholar
• HUANG Y, HONG J, ZHENG S, et al. Elimination pathways of systemically delivered siRNA. Mol Ther. 2011;19(2):381–385. DOI:10.1038/mt.2010.266
   PubMed Web of Science ®Google Scholar
• VAN DE Water FM, BOERMAN OC, WOUTERSE AC, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34(8):1393–1397. DOI:10.1124/dmd.106.009555
   PubMed Web of Science ®Google Scholar
• GEARY RS, NORRIS D, YU R, et al. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Delivery Rev. 2015;87:46–51.
   PubMed Web of Science ®Google Scholar
• PARDRIDGE WM. The blood-brain barrier and neurotherapeutics. NeuroRx. 2005;2(1):1–2.
   PubMedGoogle Scholar
• BANKS WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275–292.
   PubMed Web of Science ®Google Scholar
• MIAO L, NEWBY JM, LIN CM, et al. The binding site barrier elicited by tumor-associated fibroblasts interferes disposition of nanoparticles in stroma-vessel type tumors. ACS Nano. 2016;10(10):9243–9258. DOI:10.1021/acsnano.6b02776
   PubMed Web of Science ®Google Scholar
• DILNAWAZ F, SINGH A, MEWAR S, et al. The transport of non-surfactant based paclitaxel loaded magnetic nanoparticles across the blood brain barrier in a rat model. Biomaterials. 2012;33(10):2936–2951. DOI:10.1016/j.biomaterials.2011.12.046
   PubMed Web of Science ®Google Scholar
• TARASOV VV, CHUBAREV VN, ASHRAF GM, et al. How cancer cells resist chemotherapy: design and development of drugs targeting protein-protein interactions. Curr Top Med Chem. 2019;19(6):394–412. DOI:10.2174/1568026619666190305130141
   PubMed Web of Science ®Google Scholar
• MITCHELL MJ, BILLINGSLEY MM, HALEY RM, et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. DOI:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• SHU SA, WANG J, TAO MH, et al. Gene therapy for autoimmune disease. Clin Rev Allergy Immunol. 2015;49(2):163–176. DOI:10.1007/s12016-014-8451-x
   PubMed Web of Science ®Google Scholar
• RESNIER P, MONTIER T, MATHIEU V, et al. A review of the current status of siRNA nanomedicines in the treatment of cancer. Biomaterials. 2013;34(27):6429–6443. DOI:10.1016/j.biomaterials.2013.04.060
   PubMed Web of Science ®Google Scholar
• WANG Y, BRUGGEMAN KF, FRANKS S, et al. Is viral vector gene delivery more effective using biomaterials? Adv Healthc Mater. 2021;10(1):2001238. DOI:10.1002/adhm.202001238
   PubMed Web of Science ®Google Scholar
• ZHENG M, TAO W, ZOU Y, et al. Nanotechnology-based strategies for siRNA brain delivery for disease therapy. Trends Biotechnol. 2018;36(5):562–575. DOI:10.1016/j.tibtech.2018.01.006
   PubMed Web of Science ®Google Scholar
• FINER M, GLORIOSO J. A brief account of viral vectors and their promise for gene therapy. Genet Ther. 2017;24(1):1–2.
   PubMed Web of Science ®Google Scholar
• KRUPOVIC M, BLOMBERG J, COFFIN JM, et al. Ortervirales: new virus order unifying five families of reverse-transcribing viruses. J Virol. 2018;92(12):e00515–18. DOI:10.1128/JVI.00515-18
   PubMed Web of Science ®Google Scholar
• XU L, MEI M, HASKINS ME, et al. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice. Thromb Res. 2007;120(2):269–280. DOI:10.1016/j.thromres.2006.09.010
   PubMed Web of Science ®Google Scholar
• NALDINI L, BLOMER U, GALLAY P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263–267. DOI:10.1126/science.272.5259.263
   PubMed Web of Science ®Google Scholar
• AGHI M, HOCHBERG F, BREAKEFIELD XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2000;2(3):148–164.
   PubMed Web of Science ®Google Scholar
• SHIRLEY JL, DE Jong YP, TERHORST C, et al. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709–722. DOI:10.1016/j.ymthe.2020.01.001
   PubMed Web of Science ®Google Scholar
• MOHAMMADINEJAD R, DEHSHAHRI A, MADAMSETTY VS, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release. 2020;325:249–275.
   PubMed Web of Science ®Google Scholar
• S Dokka DT, SHI X, CASTRANOVA V, et al. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res. 2000;17(5):521–525.
   PubMed Web of Science ®Google Scholar
• GUO P, COBAN O, SNEAD NM, et al. Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Delivery Rev. 2010;62(6):650–666. DOI:10.1016/j.addr.2010.03.008
   PubMed Web of Science ®Google Scholar
• KESHARWANI P, TEKADE RK, GAJBHIYE V, et al. Cancer targeting potential of some ligand-anchored poly(propylene imine) dendrimers: a comparison. Nanomedicine. 2011;7(3):295–304. DOI:10.1016/j.nano.2010.10.010
   PubMed Web of Science ®Google Scholar
• SINGH A, TRIVEDI P, JAIN NK. Advances in siRNA delivery in cancer therapy. Artif Cells Nanomed Biotechnol. 2018;46(2):274–283.
   PubMed Web of Science ®Google Scholar
• LIU QY, ZHU JQ, SUN T, et al. Porphyrin nanotubes composed of highly ordered molecular arrays prepared by anodic aluminum template method. RSC Adv. 2013;3(8):2765–2769. DOI:10.1039/c2ra21364h
   Web of Science ®Google Scholar
• DIXIT S, NOVAK T, MILLER K, et al. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 2015;7(5):1782–1790. DOI:10.1039/C4NR04853A
   PubMed Web of Science ®Google Scholar
• WEBBER MJ, LANGER R. Drug delivery by supramolecular design. Chem Soc Rev. 2017;46(21):6600–6620.
   PubMed Web of Science ®Google Scholar
• HUANG Q, LI S, DING YF, et al. Macrocycle-wrapped polyethylenimine for gene delivery with reduced cytotoxicity. Biomater Sci. 2018;6(5):1031–1039. DOI:10.1039/C8BM00022K
   PubMed Web of Science ®Google Scholar
• GENG WC, HUANG Q, XU Z, et al. Gene delivery based on macrocyclic amphiphiles. Theranostics. 2019;9(11):3094–3106. DOI:10.7150/thno.31914
   PubMed Web of Science ®Google Scholar
• LEBRON JA, LOPEZ-CORNEJO P, OSTOS FJ. Supramolecular systems for gene and drug delivery. Pharmaceutics. 2022;14(3):471.
   PubMed Web of Science ®Google Scholar
• ASELA I, DONOSO-GONZALEZ O, YUTRONIC N, et al. β-cyclodextrin-based nanosponges functionalized with drugs and gold nanoparticles. Pharmaceutics. 2021;13(4):513. DOI:10.3390/pharmaceutics13040513
   PubMed Web of Science ®Google Scholar
• GOMEZ-GONZALEZ B, GARCIA-RIO L, BASILIO N, et al. Molecular recognition by pillar[5]arenes: evidence for simultaneous electrostatic and hydrophobic interactions. Pharmaceutics. 2021;14(1):60. DOI:10.3390/pharmaceutics14010060
   PubMed Web of Science ®Google Scholar
• LEBRON JA, LOPEZ-LOPEZ M, GARCIA-CALDERON CB, et al. Multivalent calixarene-based liposomes as platforms for gene and drug delivery. Pharmaceutics. 2021;13(8):1250. DOI:10.3390/pharmaceutics13081250
   PubMed Web of Science ®Google Scholar
• KARAVA V, SIAMIDI A, VLACHOU M, et al. Poly(l-lactic acid)-co-poly(butylene adipate) new block copolymers for the preparation of drug-loaded long acting injectable microparticles. Pharmaceutics. 2021;13(7):930. DOI:10.3390/pharmaceutics13070930
   PubMed Web of Science ®Google Scholar
• TANG L, ZHANG A, MEI Y, et al. NIR light-triggered chemo-phototherapy by ICG functionalized MWNTs for synergistic tumor-targeted delivery. Pharmaceutics. 2021;13(12):2145. DOI:10.3390/pharmaceutics13122145
   PubMed Web of Science ®Google Scholar
• MBATHA LS, MAIYO F, DANIELS A, et al. Dendrimer-coated gold nanoparticles for efficient folate-targeted mRNA delivery in vitro. Pharmaceutics. 2021;13(6):900. DOI:10.3390/pharmaceutics13060900
   PubMed Web of Science ®Google Scholar
• YUE L, SUN T, YANG K, et al. Supramolecular nanovesicles for synergistic glucose starvation and hypoxia-activated gene therapy of cancer. Nanoscale. 2021;13(21):9570–9576. DOI:10.1039/D1NR02159A
   PubMed Web of Science ®Google Scholar
• TORRES CE, CIFUENTES J, GOMEZ SC, et al. Microfluidic synthesis and purification of magnetoliposomes for potential applications in the gastrointestinal delivery of difficult-to-transport drugs. Pharmaceutics. 2022;14(2):315. DOI:10.3390/pharmaceutics14020315
   PubMed Web of Science ®Google Scholar
• ILHAMI FB, BAYLE EA, CHENG CC. Complementary nucleobase interactions drive co-assembly of drugs and nanocarriers for selective cancer chemotherapy. Pharmaceutics. 2021;13(11):1929.
   PubMed Web of Science ®Google Scholar
• JAGUSIAK A, CHLOPAS K, ZEMANEK G, et al. Interaction of supramolecular congo red and congo red-doxorubicin complexes with proteins for drug carrier design. Pharmaceutics. 2021;13(12):2027. DOI:10.3390/pharmaceutics13122027
   PubMed Web of Science ®Google Scholar
• MAY C, RIVELLA S, CALLEGARI J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406(6791):82–86. DOI:10.1038/35017565
   PubMed Web of Science ®Google Scholar
• WALTHER W, PETKOV S, KUVARDINA ON, et al. Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3- and -4-overexpressing tumors. Genet Ther. 2012;19(5):494–503. DOI:10.1038/gt.2011.136
   PubMed Web of Science ®Google Scholar
• Antonio DI Stasi S-KT, DOTTI GIANPIETRO, FUJITA YURIKO, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–1683.
   PubMed Web of Science ®Google Scholar
• YUE L, YANG K, WEI J, et al. Supramolecular vesicles based on gold nanorods for precise control of gene therapy and deferred photothermal therapy. CCS Chemistry. 2022;4(5):1745–1757. DOI:10.31635/ccschem.021.202101029
   Google Scholar
• NEGRE O, EGGIMANN AV, BEUZARD Y, et al. Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene. Hum Gene Ther. 2016;27(2):148–165. DOI:10.1089/hum.2016.007
   PubMed Web of Science ®Google Scholar
• GILBERT C. Changing challenges in the control of blindness in children. Eye (Lond). 2007;21(10):1338–1343.
   PubMed Web of Science ®Google Scholar
• CHEN C, YANG Z, TANG X. Chemical modifications of nucleic acid drugs and their delivery systems for gene-based therapy. Med Res Rev. 2018;38(3):829–869.
   PubMed Web of Science ®Google Scholar
• ROBERTS TC, LANGER R, WOOD MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–694. DOI:10.1038/s41573-020-0075-7
   PubMed Web of Science ®Google Scholar
• YAMADA Y. Nucleic acid drugs—current status, issues, and expectations for exosomes. Cancers (Basel). 2021;13(19):5002.
   PubMed Web of Science ®Google Scholar
• BUMCROT D, MANOHARAN M, KOTELIANSKY V, et al. Rnai therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2(12):711–719. DOI:10.1038/nchembio839
   PubMed Web of Science ®Google Scholar
• TAN X, JIA F, WANG P, et al. Nucleic acid-based drug delivery strategies. J Control Release. 2020;323:240–252.
   PubMed Web of Science ®Google Scholar
• WU H, LIMA WF, ZHANG H, et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem. 2004;279(17):17181–17189. DOI:10.1074/jbc.M311683200
   PubMed Web of Science ®Google Scholar
• SI ML, ZHU S, WU H, et al. MiR-21-mediated tumor growth. Oncogene. 2007;26(19):2799–2803. DOI:10.1038/sj.onc.1210083
   PubMed Web of Science ®Google Scholar
• KRUTZFELDT J, RAJEWSKY N, BRAICH R, et al. Silencing of microRnas in vivo with ‘antagomirs. Nature. 2005;438(7068):685–689. DOI:10.1038/nature04303
   PubMed Web of Science ®Google Scholar
• ECKSTEIN F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24(6):374–387.
   PubMed Web of Science ®Google Scholar
• CROOKE ST. Molecular mechanisms of antisense oligonucleotides. Nucleic Acid Ther. 2017;27(2):70–77.
   PubMed Web of Science ®Google Scholar
• WANG J, MI P, LIN G, et al. Imaging-guided delivery of RNAi for anticancer treatment. Adv Drug Delivery Rev. 2016;104:44–60.
   PubMed Web of Science ®Google Scholar
• TATIPARTI K, SAU S, KASHAW SK, et al. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials (Basel). 2017;7(4):1–17.
   Google Scholar
• CHEN X, MANGALA LS, RODRIGUEZ-AGUAYO C, et al. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018;37(1):107–124. DOI:10.1007/s10555-017-9717-6
   PubMed Web of Science ®Google Scholar
• XIN Y, HUANG M, GUO WW, et al. Nano-based delivery of RNAi in cancer therapy. Mol Cancer. 2017;16(1):134. DOI:10.1186/s12943-017-0683-y
   PubMed Web of Science ®Google Scholar
• MILLER T, CUDKOWICZ M, SHAW PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109–119. DOI:10.1056/NEJMoa2003715
   PubMed Web of Science ®Google Scholar
• ODATE S, VESCHI V, YAN S, et al. Inhibition of STAT3 with the generation 2.5 antisense oligonucleotide, AZD9150, decreases neuroblastoma tumorigenicity and increases chemosensitivity. Clin Cancer Res. 2017;23(7):1771–1784. DOI:10.1158/1078-0432.CCR-16-1317
   PubMed Web of Science ®Google Scholar
• DEVOS SL, MILLER RL, SCHOCH KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481. DOI:10.1126/scitranslmed.aag0481
   PubMed Web of Science ®Google Scholar
• PERRY CM, BALFOUR JAB. Fomivirsen [J]. Drugs. 1999;57(3):375–380.
   PubMed Web of Science ®Google Scholar
• KEAM SJ. Inotersen: first global approval. Drugs. 2018;78(13):1371–1376.
   PubMed Web of Science ®Google Scholar
• HAIR P, CAMERON F, MCKEAGE K. Mipomersen sodium: first global approval. Drugs. 2013;73(5):487–493.
   PubMed Web of Science ®Google Scholar
• INOUYE M. The first discovery of RNA interference by RNA restriction enzymes to inhibit protein synthesis. Gene. 2017;597:78–79.
   PubMed Web of Science ®Google Scholar
• JARVE A, MULLER J, KIM IH, et al. Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Res. 2007;35(18):e124. DOI:10.1093/nar/gkm694
   PubMed Web of Science ®Google Scholar
• RAO DD, VORHIES JS, SENZER N, et al. siRNA vs. shRNA: similarities and differences. Adv Drug Delivery Rev. 2009;61(9):746–759. doi: 10.1016/j.addr.2009.04.004
   PubMed Web of Science ®Google Scholar
• HUANG H, ZHANG C, WANG B, et al. Transduction with lentiviral vectors altered the expression profile of host MicroRNAs. J Virol. 2018;92(18):e00503–18. DOI:10.1128/JVI.00503-18
   PubMed Web of Science ®Google Scholar
• ZHANG WW, LI L, LI D, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Hum Gene Ther. 2018;29(2):160–179. DOI:10.1089/hum.2017.218
   PubMed Web of Science ®Google Scholar
• DEVINCENZO J, LAMBKIN-WILLIAMS R, WILKINSON T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800–8805. DOI:10.1073/pnas.0912186107
   PubMed Web of Science ®Google Scholar
• SUBRAMANYA S, KIM SS, MANJUNATH N, et al. RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA? Expert Opin Biol Ther. 2010;10(2):201–213. DOI:10.1517/14712590903448158
   PubMed Web of Science ®Google Scholar
• ASHFAQ UA, YOUSAF MZ, ASLAM M, et al. siRnas: potential therapeutic agents against hepatitis C virus. Virol J. 2011;8:276.
   PubMed Web of Science ®Google Scholar
• DIFIGLIA M, SENA-ESTEVES M, CHASE K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104(43):17204–17209. DOI:10.1073/pnas.0708285104
   PubMed Web of Science ®Google Scholar
• FARAH MH. Rnai silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv. 2007;4(2):161–167.
   PubMedGoogle Scholar
• LI T, KOSHY S, FOLKESSON HG. RNA interference for CFTR attenuates lung fluid absorption at birth in rats. Respir Res. 2008;9:55.
   PubMed Web of Science ®Google Scholar
• COURTIES G, PRESUMEY J, DUROUX-RICHARD I, et al. RNA interference-based gene therapy for successful treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2009;9(5):535–538. DOI:10.1517/14712590902926089
   PubMed Web of Science ®Google Scholar
• COHEN ZR, RAMISHETTI S, PESHES-YALOZ N, et al. Localized RNAi therapeutics of chemoresistant grade iv glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano. 2015;9(2):1581–1591. DOI:10.1021/nn506248s
   PubMed Web of Science ®Google Scholar
• KARLIKOW M, GOIC B, MONGELLI V, et al. Drosophila cells use nanotube-like structures to transfer dsRNA and RNAi machinery between cells. Sci Rep. 2016;6:27085.
   PubMed Web of Science ®Google Scholar
• JIANG T, QIAO Y, RUAN W, et al. Cation-Free siRNA micelles as effective drug delivery platform and potent RNAi nanomedicines for glioblastoma therapy. Adv Mater. 2021;33(45):e2104779. DOI:10.1002/adma.202104779
   PubMed Web of Science ®Google Scholar
• KHAN A, ALJARBOU AN, ALDEBASI YH, et al. Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 targeted Fab’-Immunoliposomes for gene silencing in breast cancer cells. Int J Nanomedicine. 2020;15:5575–5589.
   PubMed Web of Science ®Google Scholar
• E DJ, BARNES C, KHAN O, et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol. 2014;9(8):648–655. DOI:10.1038/nnano.2014.84
   PubMed Web of Science ®Google Scholar
• ZHENG M, JIANG T, YANG W, et al. The siRnasome: a cation‐free and versatile nanostructure for siRNA and drug co‐delivery. Angewandte Chemie. 2019;58(15):4938–4942. DOI:10.1002/anie.201814289
   Google Scholar
• SANTEL A, ALEKU M, KEIL O, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Genet Ther. 2006;13(16):1222–1234. DOI:10.1038/sj.gt.3302777
   PubMed Web of Science ®Google Scholar
• LEE YW, HWANG YE, LEE JY, et al. VEGF siRNA delivery by a cancer-specific cell-penetrating peptide. J Microbiol Biotechnol. 2018;28(3):367–374. DOI:10.4014/jmb.1711.11025
   PubMed Web of Science ®Google Scholar
• HOY SM. Patisiran: first global approval. Drugs. 2018;78(15):1625–1631.
   PubMed Web of Science ®Google Scholar
• SETTEN RL, ROSSI JJ, HAN SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–446.
   PubMed Web of Science ®Google Scholar
• SAW PE, SONG EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63(4):485–500.
   PubMed Web of Science ®Google Scholar
• RAAL FJ, KALLEND D, RAY KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382(16):1520–1530. DOI:10.1056/NEJMoa1913805
   PubMed Web of Science ®Google Scholar
• LI LC, OKINO ST, ZHAO H, et al. Small dsRnas induce transcriptional activation in human cells. Proc Natl Acad Sci U S A. 2006;103(46):17337–17342. DOI:10.1073/pnas.0607015103
   PubMed Web of Science ®Google Scholar
• VOUTILA J, REEBYE V, ROBERTS TC, et al. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol Ther. 2017;25(12):2705–2714. DOI:10.1016/j.ymthe.2017.07.018
   PubMed Web of Science ®Google Scholar
• TAN CP, SINIGAGLIA L, GOMEZ V, et al. RNA activation—A novel approach to therapeutically upregulate gene transcription. Molecules. 2021;26(21):6530. DOI:10.3390/molecules26216530
   PubMed Web of Science ®Google Scholar
• DYKXHOORN DM, NOVINA CD, SHARP PA. Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003;4(6):457–467.
   PubMed Web of Science ®Google Scholar
• PLACE RF, NOONAN EJ, FOLDES-PAPP Z, et al. Defining features and exploring chemical modifications to manipulate RNAa activity. Curr Pharm Biotechnol. 2010;11(5):518–526. DOI:10.2174/138920110791591463
   PubMed Web of Science ®Google Scholar
• REEBYE V, SAETROM P, J MP, et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology. 2014;59(1):216–227. DOI:10.1002/hep.26669
   PubMed Web of Science ®Google Scholar
• JANOWSKI BA, YOUNGER ST, HARDY DB, et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol. 2007;3(3):166–173. DOI:10.1038/nchembio860
   PubMed Web of Science ®Google Scholar
• KANG MR, YANG G, PLACE RF, et al. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth. Cancer Res. 2012;72(19):5069–5079. DOI:10.1158/0008-5472.CAN-12-1871
   PubMed Web of Science ®Google Scholar
• KOSAKA M, KANG MR, YANG G, et al. Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells. Nucleic Acid Ther. 2012;22(5):335–343. DOI:10.1089/nat.2012.0354
   PubMed Web of Science ®Google Scholar
• PLACE RF, WANG J, NOONAN EJ, et al. Formulation of small activating RNA into lipidoid nanoparticles inhibits xenograft prostate tumor growth by inducing p21 expression. Mol Ther Nucleic Acids. 2012;1:e15.
   PubMedGoogle Scholar
• A SDS, BRYSZEWSKA M. Poly(amidoamine) dendrimer complexes as a platform for gene delivery. Expert Opin Drug Deliv. 2013;10(12):1687–1698.
   PubMed Web of Science ®Google Scholar
• REEBYE V, HUANG KW, LIN V, et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene. 2018;37(24):3216–3228. DOI:10.1038/s41388-018-0126-2
   PubMed Web of Science ®Google Scholar
• HUANG KW, TAN CP, REEBYE V, et al. MTL-CEBPA combined with immunotherapy or RFA enhances immunological anti-tumor response in preclinical models. Int J Mol Sci. 2021;22(17):9168. DOI:10.3390/ijms22179168
   PubMed Web of Science ®Google Scholar
• HASHIMOTO A, SARKER D, REEBYE V, et al. Upregulation of C/EBPalpha inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and patients with cancer. Clin Cancer Res. 2021;27(21):5961–5978. DOI:10.1158/1078-0432.CCR-21-0986
   PubMed Web of Science ®Google Scholar
• SARKER D, PLUMMER R, MEYER T, et al. MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-alpha, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial. Clin Cancer Res. 2020;26(15):3936–3946. DOI:10.1158/1078-0432.CCR-20-0414
   PubMed Web of Science ®Google Scholar
• KONERMANN S, BRIGHAM MD, TREVINO AE, et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature. 2015;517(7536):583–588. DOI:10.1038/nature14136
   PubMed Web of Science ®Google Scholar
• CHAVEZ A, TUTTLE M, PRUITT BW, et al. Comparison of Cas9 activators in multiple species. Nat Methods. 2016;13(7):563–567. DOI:10.1038/nmeth.3871
   PubMed Web of Science ®Google Scholar
• ZHOU H, LIU J, ZHOU C, et al. In vivo simultaneous transcriptional activation of multiple genes in the brain using CRISPR-dCas9-activator transgenic mice. Nat Neurosci. 2018;21(3):440–446. DOI:10.1038/s41593-017-0060-6
   PubMed Web of Science ®Google Scholar
• DAMAS ETR, SUKHOVERSHIN R, BOADA C, et al. The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 2021;9:628137.
   PubMed Web of Science ®Google Scholar
• HOUSDEN BE, MUHAR M, GEMBERLING M, et al. Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nat Rev Genet. 2017;18(1):24–40. DOI:10.1038/nrg.2016.118
   PubMed Web of Science ®Google Scholar
• WANG H, YANG H, SHIVALILA CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell. 2013;153(4):910–918. DOI:10.1016/j.cell.2013.04.025
   PubMed Web of Science ®Google Scholar
• BENGTSSON NE, HALL JK, ODOM GL, et al. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8:14454.
   PubMed Web of Science ®Google Scholar
• OMER L, HUDSON EA, ZHENG S, et al. CRISPR correction of a homozygous low-density lipoprotein receptor mutation in familial hypercholesterolemia induced pluripotent stem cells. Hepatol Commun. 2017;1(9):886–898. DOI:10.1002/hep4.1110
   PubMed Web of Science ®Google Scholar
• ZHANG D, WANG G, YU X, et al. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy. Nat Nanotechnol. 2022;17(7):777–787. DOI:10.1038/s41565-022-01122-3
   PubMed Web of Science ®Google Scholar
• ZHANG F, WEN Y, GUO X. CRISPR/Cas9 for genome editing: progress, implications and challenges. Hum Mol Genet. 2014;23(R1):R40–6.
   PubMed Web of Science ®Google Scholar
• MUSUNURU K. The hope and hype of CRISPR-Cas9 genome editing: a review. JAMA Cardiol. 2017;2(8):914–919.
   PubMed Web of Science ®Google Scholar
• KEENER AB. Delivering the goods: scientists seek a way to make CRISPR-Cas gene editing more targeted. Nat Med. 2015;21(11):1239–1241.
   PubMed Web of Science ®Google Scholar
• NELSON CE, GERSBACH CA. Engineering delivery vehicles for genome editing. Annu Rev Chem Biomol Eng. 2016;7:637–662.
   PubMed Web of Science ®Google Scholar
• WILBIE D, WALTHER J, MASTROBATTISTA E. Delivery aspects of CRISPR/cas for in vivo genome editing. Acc Chem Res. 2019;52(6):1555–1564.
   PubMed Web of Science ®Google Scholar
• LAFOUNTAINE JS, FATHE K, SMYTH HD. Delivery and therapeutic applications of gene editing technologies ZFNs, TALENs, and CRISPR/Cas9. Int J Pharm. 2015;494(1):180–194.
   PubMedGoogle Scholar
• GORI JL, HSU PD, MAEDER ML, et al. Delivery and specificity of CRISPR-Cas9 genome editing technologies for human gene therapy. Hum Gene Ther. 2015;26(7):443–451. DOI:10.1089/hum.2015.074
   PubMed Web of Science ®Google Scholar
• LIU L, CAO J, CHANG Q, et al. In Vivo Exon replacement in the mouse Atp7b gene by the Cas9 system. Hum Gene Ther. 2019;30(9):1079–1092. DOI:10.1089/hum.2019.037
   PubMed Web of Science ®Google Scholar
• MAEDER ML, GERSBACH CA. Genome-editing technologies for gene and cell therapy. Mol Ther. 2016;24(3):430–446.
   PubMed Web of Science ®Google Scholar
• WANG AY, PENG PD, EHRHARDT A, et al. Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum Gene Ther. 2004;15(4):405–413. DOI:10.1089/104303404322959551
   PubMed Web of Science ®Google Scholar
• YANG Y, WANG L, BELL P, et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nature Biotechnol. 2016;34(3):334–338. DOI:10.1038/nbt.3469
   PubMed Web of Science ®Google Scholar
• WU Z, YANG H, COLOSI P. Effect of genome size on AAV vector packaging. Mol Ther. 2010;18(1):80–86.
   PubMed Web of Science ®Google Scholar
• CHEN X, GONCALVES MA. Engineered viruses as genome editing devices. Mol Ther. 2016;24(3):447–457.
   PubMed Web of Science ®Google Scholar
• PETROS RA, DESIMONE JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9(8):615–627.
   PubMed Web of Science ®Google Scholar
• GU Z, BISWAS A, ZHAO M, et al. Tailoring nanocarriers for intracellular protein delivery. Chem Soc Rev. 2011;40(7):3638–3655. DOI:10.1039/c0cs00227e
   PubMed Web of Science ®Google Scholar
• YAN M, DU J, GU Z, et al. A novel intracellular protein delivery platform based on single-protein nanocapsules. Nat Nanotechnol. 2010;5(1):48–53. DOI:10.1038/nnano.2009.341
   PubMed Web of Science ®Google Scholar
• KUAN SL, NG DY, WU Y, et al. pH responsive Janus-like supramolecular fusion proteins for functional protein delivery. J Am Chem Soc. 2013;135(46):17254–17257. DOI:10.1021/ja4084122
   PubMed Web of Science ®Google Scholar
• PELEGRI-O’day EM, LIN EW, MAYNARD HD. Therapeutic protein-polymer conjugates: advancing beyond PEGylation. J Am Chem Soc. 2014;136(41):14323–14332.
   PubMed Web of Science ®Google Scholar
• JIANG Y, LU H, CHEN F, et al. Pegylated albumin-based polyion complex micelles for protein delivery. Biomacromolecules. 2016;17(3):808–817. DOI:10.1021/acs.biomac.5b01537
   PubMed Web of Science ®Google Scholar
• KERN HB, SRINIVASAN S, CONVERTINE AJ, et al. Enzyme-cleavable polymeric micelles for the intracellular delivery of proapoptotic peptides. Mol Pharm. 2017;14(5):1450–1459. DOI:10.1021/acs.molpharmaceut.6b01178
   PubMedGoogle Scholar
• XIONG H, ZHOU Y, ZHOU Q, et al. Nanocapsule assemblies as effective enzyme delivery systems against hyperuricemia. Nanomedicine. 2016;12(6):1557–1566. DOI:10.1016/j.nano.2016.02.010
   PubMed Web of Science ®Google Scholar
• ZOU Y, SUN X, YANG Q, et al. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy. Sci Adv. 2022;8(16):eabm8011. DOI:10.1126/sciadv.abm8011
   PubMed Web of Science ®Google Scholar
• SHABBIR MAB, SHABBIR MZ, WU Q, et al. CRISPR-cas system: biological function in microbes and its use to treat antimicrobial resistant pathogens. Ann Clin Microbiol Antimicrob. 2019;18(1):21. DOI:10.1186/s12941-019-0317-x
   PubMed Web of Science ®Google Scholar
• FU A, TANG R, HARDIE J, et al. Promises and pitfalls of intracellular delivery of proteins. Bioconjugate Chem. 2014;25(9):1602–1608. DOI:10.1021/bc500320j
   PubMed Web of Science ®Google Scholar
• BIAGIONI A, LAURENZANA A, MARGHERI F, et al. Delivery systems of CRISPR/Cas9-based cancer gene therapy. J Biol Eng. 2018;12:33.
   PubMed Web of Science ®Google Scholar
• LI L, HU S, CHEN X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities. Biomaterials. 2018;171:207–218.
   PubMed Web of Science ®Google Scholar
• EOH J, GU L. Biomaterials as vectors for the delivery of CRISPR-Cas9. Biomater Sci. 2019;7(4):1240–1261.
   PubMed Web of Science ®Google Scholar
• WANG HX, LI M, LEE CM, et al. Crispr/cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev. 2017;117(15):9874–9906. DOI:10.1021/acs.chemrev.6b00799
   PubMed Web of Science ®Google Scholar
• WEI T, CHENG Q, MIN YL, et al. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232. DOI:10.1038/s41467-020-17029-3
   PubMed Web of Science ®Google Scholar
• CHEN G, ABDEEN AA, WANG Y, et al. A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing. Nat Nanotechnol. 2019;14(10):974–980. DOI:10.1038/s41565-019-0539-2
   PubMed Web of Science ®Google Scholar
• GAO X, TAO Y, LAMAS V, et al. Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents. Nature. 2018;553(7687):217–221. DOI:10.1038/nature25164
   PubMed Web of Science ®Google Scholar
• VAN Der MEEL R. Nanotechnology for organ-tunable gene editing. Nature Nanotechnol. 2020;15(4):253–255.
   PubMed Web of Science ®Google Scholar
• CHENG Q, WEI T, FARBIAK L, et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313–320. DOI:10.1038/s41565-020-0669-6
   PubMed Web of Science ®Google Scholar
• CHEN Z, LIU F, CHEN Y, et al. Targeted delivery of CRISPR/Cas9-mediated cancer gene therapy via liposome-templated hydrogel nanoparticles. Adv Funct Mater. 2017;27(46):1703036. DOI:10.1002/adfm.201703036
   PubMed Web of Science ®Google Scholar
• LIU Q, ZHAO K, WANG C, et al. Multistage delivery nanoparticle facilitates efficient CRISPR/dCas9 activation and tumor growth suppression in vivo. Adv Sci. 2019;6(1):1801423. DOI:10.1002/advs.201801423
   Web of Science ®Google Scholar
• LEE K, CONBOY M, PARK HM, et al. Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat Biomed Eng. 2017;1(11):889–901. DOI:10.1038/s41551-017-0137-2
   PubMed Web of Science ®Google Scholar
• WAREJONCAS Z, CAMPBELL JM, MARTINEZ-GALVEZ G, et al. Precision gene editing technology and applications in nephrology. Nat Rev Nephrol. 2018;14(11):663–677. DOI:10.1038/s41581-018-0047-x
   PubMed Web of Science ®Google Scholar
• TANG T, GAO MH, HAMMOND HK. Prospects for gene transfer for clinical heart failure. Genet Ther. 2012;19(6):606–612.
   PubMed Web of Science ®Google Scholar
• MOODLEY S, WEBER F, MULLIGAN LM. The evolving clinical, genetic and therapeutic landscape of multiple endocrine neoplasia type 2. Endocr Relat Cancer. 2018;25(2):E1–4.
   PubMed Web of Science ®Google Scholar
• CHEN HC, LIU DY, GUO ZJ. Endogenous stimuli-responsive nanocarriers for drug delivery. Chem Lett. 2016;45(3):242–249.
   Web of Science ®Google Scholar
• GURAGAIN S, BASTAKOTI BP, MALGRAS V, et al. Multi-stimuli-responsive polymeric materials. Chemistry. 2015;21(38):13164–13174. DOI:10.1002/chem.201501101
   PubMed Web of Science ®Google Scholar
• SINGH B, MAHARJAN S, PARK TE, et al. Tuning the buffering capacity of polyethylenimine with glycerol molecules for efficient gene delivery: staying in or out of the endosomes. Macromol biosci. 2015;15(5):622–635. DOI:10.1002/mabi.201400463
   PubMed Web of Science ®Google Scholar
• ZAKERI A, KOUHBANANI MAJ, BEHESHTKHOO N, et al. Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a developing horizon. Nano Rev Exp. 2018;9(1):1488497. DOI:10.1080/20022727.2018.1488497
   PubMed Web of Science ®Google Scholar
• YAO Q, KOU L, TU Y, et al. MMP-Responsive ‘Smart’ drug delivery and tumor targeting. Trends Pharmacol Sci. 2018;39(8):766–781. DOI:10.1016/j.tips.2018.06.003
   PubMed Web of Science ®Google Scholar